Release Subtitle:
Researchers develop a tri-culture heart-on-a-chip model of cardiomyocytes, fibroblasts, and endothelial cells to mimic in vivo cardiac behavior

Release Summary Text:
Organ-on-a-chip technology, combining tissue engineering and microfluidics, offers an alternative to animal models by creating in vitro biological systems that replicate the tissue-level microenvironment. A recent study developed a heart-on-a-chip model with cardiomyocytes, fibroblasts, and vascular endothelial cells, achieving a 3D multilayer cell model that demonstrated both structural and functional integrity, suitable for studying disease models and predicting drug safety and efficacy.

Full text of release:
To address the global burden of cardiovascular diseases, there's an urgent need for early-stage screening technologies and effective therapeutics. However, the medical research community faces significant challenges, including the high failure rate of candidate drugs in clinical trials and the ethical concerns surrounding the use of laboratory animals. Static cell culture models also fall short in replicating the complex tissue-level microenvironment.

Recent advancements in tissue engineering and microfluidics have paved the way for the development of heart-on-a-chip models. These models aim to simulate the roles of cardiomyocytes, fibroblasts, and endothelial cells—each crucial for normal cardiac function. Cardiomyocytes manage heart contraction and electric signaling, fibroblasts maintain structural integrity, and endothelial cells regulate the vascular system.

Previous studies have reported bi-culture systems incorporating induced pluripotent stem cell (iPSC)-derived cardiomyocytes and fibroblasts, excluding endothelial cell functions. To address this gap, Associate Professor Ken Takahashi, Professor Keiji Naruse, and Dr. Yun Liu, affiliated with the Graduate School of Medicine, Dentistry and Pharmaceutical Sciences at Okayama University, Japan, published a study in Scientific Reports on 08 August 2024. “In this study, we have developed a 3D heart-on-a-chip model using iPSCs, fibroblasts, and endothelial cells, designed to mimic the anatomical structure of cardiac tissue,” comments Dr. Takahashi.

The heart-on-a-chip model was designed to include two channels separated by a central membrane. The human umbilical vein endothelial cells (HUVECs) were seeded in the bottom channel and iPSCs, and human gingival fibroblasts (HGFs) were seeded in the top channel. The microfluidic channels mimicked intracellular blood flow.

The study successfully replicated endothelial cell morphology and functionality. In response to shear stress simulation, endothelial cells aligned themselves parallel to the flow of the medium by orienting F-actin appropriately, thereby mimicking in vivo conditions. CD31, a cell-cell junction protein, plays a crucial role in regulating vascular permeability. Increased vascular permeability can lead to endothelial dysfunction and contribute to the progression of atherosclerosis. This study demonstrated that medium flow promoted endothelial cell integrity, confirmed by CD31 staining and lower vascular permeability. Additionally, the presence of cardiac troponin t (cTnT) and IRX4 (cardiomyocyte markers) indicated high contractility. “The percentage of cells co-expressing cTnT and IRX4 was notably elevated in the tri-culture group (56.3 ± 14.7%, n = 5) in contrast to the bi-culture group (30.2 ± 13.5%, n = 6) (P < 0.05),” notes Dr. Takahashi.

This study demonstrated the functionality of human cardiac tissue by replicating the effects of noradrenalin (NA) on cardiomyocytes. “The cardiac tissue exhibited a dose-dependent increase in heart rate in response to NA,” notes Dr. Takahashi. Additionally, administration of nifedipine, a dihydropyridine calcium channel blocker, decreased cardiac contractility and prolonged the QT interval, suggesting potential cardiotoxicity.

Further research should focus on incorporating inflammatory responses with immune cells to enhance the heart-on-a-chip model. Extending the viability of organ models beyond 60 days will significantly reduce costs and achieve important research goals.

Creating organ-on-chip models using patient-derived pluripotent cells is transforming personalized medicine by providing safer, more effective drugs and eliminating the need for animal testing. This advancement not only makes research more ethical but also boosts our ability to study cardiac functions, predict drug responses, and accelerate the development of innovative therapies.


Release URL:
https://www.eurekalert.org/news-releases/1057368

Reference:
Title of original paper: Human heart-on-a-chip microphysiological system comprising endothelial cells, fibroblasts, and iPSC-derived cardiomyocytes.
Journal: Scientific Reports
DOI:10.1038/s41598-024-68275-0

Contact Person:Ken Takahashi
Dr. Ken Takahashi is an Associate Professor at the Graduate School of Medicine, Dentistry and Pharmaceutical Sciences at Okayama University in Japan. He received his Ph.D. in Medicine from Nagoya University. Dr. Takahashi’s research focuses on organ-on-a-chip, cardiac regenerative medicine, and space medicine. He is a former visiting faculty at Harvard Medical School, where he developed a model of ischemia-reperfusion injury using organ-on-a-chip technology. Dr. Takahashi is the recipient of Award for Outstanding Research Achievement and Contribution from the Asia Pacific Society for Biology and Medical Sciences, and the Award for Outstanding Contribution to Education from the Okayama Medical Association. He serves on the boards of several journals including, Pathophysiology, AIMS Biophysics, and Hearts. Dr. Takahashi is an ironman triathlete and a torchbearer at the Tokyo 2020 Olympics.